肿瘤细胞治疗研究
FRONTIER PAPERS
Relapsed/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B-cell maturation antigen-directed chi
这些发现支持进一步研究再治疗策略和CAR-T后维持治疗方法。
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myelom
我们比较了BCMA CAR-T治疗前和BCMA CAR-T治疗后复发时CD45 + BM细胞的异质性。
All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma.
本研究阐明了 ATRA 调控 CD38 表达的一种机制，并拓展了 ATRA 在改善多发性骨髓瘤患者抗 CD38 免疫治疗方面的临床潜力。Cite Now.
Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies.
CD38在多发性骨髓瘤（MM）细胞上高表达，并在调控肿瘤发生发展中发挥作用。
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
我们的结果证实，BCMA-CD38 CAR-T细胞疗法治疗R/R MM患者是可行的，具有高缓解率、低复发率和可控的CRS，将成为R/R MM一种有前景的治疗选择。
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
双特异性BM38 CAR-T在RRMM患者中可行、安全且显著有效。
Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid.
多发性骨髓瘤（MM）在复发/难治性病例中仍具挑战性，原因是对蛋白酶体抑制剂或抗CD38抗体daratumumab（Dara）等疗法产生耐药性。
Translating B-Cell and Plasma-Cell Targeting from Oncology to Autoimmunity: Modalities, Quantitative Bridging, and a Development Roadmap.
B 细胞通过自身抗体产生、抗原提呈和细胞因子失调，以及致病性 B 细胞或浆细胞区室的持续存在，驱动 B 细胞恶性肿瘤和多种自身免疫性疾病。
The bone marrow immune ecosystem shapes daratumumab acquired resistance in plasma cell myeloma.
达雷妥尤单抗是一种抗CD38单克隆抗体，是浆细胞骨髓瘤（PCM）的有效治疗药物。
Efficacy and safety of CD38-directed CAR-T cell therapy for multiple myeloma: a systematic review and meta-analysis.
双靶点 CD38/BCMA CAR-T 在 RRMM 中显示出有前景的疗效和可控的安全性。
MEMBER ACCOUNT
登录成功会直接打开下一页。
